Bristol Haematology and Oncology Centre, University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, UK.
Queen's University Belfast and Northern Ireland Cancer Centre, Belfast, UK.
Int J Clin Pract. 2021 Aug;75(8):e14338. doi: 10.1111/ijcp.14338. Epub 2021 May 24.
To understand the awareness and use of rectal spacers for prostate cancer patients undergoing radical radiotherapy in the United Kingdom.
An expert-devised online questionnaire was completed by members of the British Uro-oncology Group (BUG).
Sixty-three specialists completed the survey (50% of BUG members at that point in time). Only 37% had used rectal spacers, mostly for private patients or those with pre-existing bowel conditions. However, many (68%) would like to use these devices in future. More than 70% of the uro-oncologists felt that bowel toxicity was underreported, but 60% believed that the use of radiotherapy without bowel toxicity was achievable with the use of rectal spacers.
The current use of rectal spacers by UK uro-oncologists for patients with localised or locally advanced prostate cancer receiving radiotherapy is low and largely restricted by resourcing issues.
了解英国接受根治性放疗的前列腺癌患者对直肠间隔器的认知和使用情况。
由英国泌尿肿瘤学组（BUG）的专家设计了在线问卷，由成员完成。
63 名专家完成了这项调查（当时 BUG 成员的 50%）。只有 37%的人使用过直肠间隔器，主要用于私人患者或有预先存在的肠道疾病的患者。然而，许多人（68%）希望在未来使用这些设备。超过 70%的泌尿肿瘤学家认为肠道毒性被低估了，但 60%的人认为使用直肠间隔器可以实现没有肠道毒性的放疗。
英国泌尿肿瘤学家目前对接受放疗的局限性或局部晚期前列腺癌患者使用直肠间隔器的情况很少，而且主要受到资源问题的限制。
